Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Melatonin | Phosphatidylserine | |
|---|---|---|
| Category | Supplements | Supplements |
| Standard Dose | 0.3-1mg for sleep onset (physiological); 3-5mg for jet lag; 10-20mg for oncological adjunct (under supervision) | 100-300mg daily |
| Timing | 30-60 minutes before desired sleep onset. For circadian phase advance: 4-6 hours before desired bedtime. Sublingual for faster onset. Dim lights 1-2 hours before taking. | With meals (fat-containing preferred for absorption). Can be taken morning or evening. Cortisol-blunting effects are relevant for evening/pre-bed dosing in stressed individuals. |
| Cycle Duration | Short-term for jet lag (3-5 days); ongoing at low dose for circadian support if needed; extended for oncological use under supervision | Ongoing; no cycling required. Clinical benefits observed from 6-12 weeks. |
| Evidence Level | strong_human | strong_human |
Melatonin (N-acetyl-5-methoxytryptamine) is synthesized from serotonin in the pineal gland, regulated by the suprachiasmatic nucleus (SCN) via the retinohypothalamic tract. It binds MT1 and MT2 G-protein coupled receptors: MT1 activation suppresses neuronal firing in the SCN (sleep onset), while MT2 modulates circadian phase shifting. Beyond sleep, melatonin is a potent antioxidant that scavenges hydroxyl radicals, peroxynitrite, and singlet oxygen, and upregulates antioxidant enzymes (GPx, SOD, catalase) via Nrf2. It has anti-inflammatory properties (NF-kB suppression), immunomodulatory effects, oncostatic activity (anti-proliferative in several cancer types), and mitochondrial protective functions.
0.3-1mg for sleep onset (physiological); 3-5mg for jet lag; 10-20mg for oncological adjunct (under supervision)
30-60 minutes before desired sleep onset. For circadian phase advance: 4-6 hours before desired bedtime. Sublingual for faster onset. Dim lights 1-2 hours before taking.
Short-term for jet lag (3-5 days); ongoing at low dose for circadian support if needed; extended for oncological use under supervision
Major phospholipid component of neuronal cell membranes (15-20% of total phospholipid pool) that maintains membrane fluidity and supports signal transduction. Serves as a cofactor for protein kinase C (PKC), Na+/K+-ATPase, and other membrane-bound enzymes critical for neurotransmitter release. Blunts HPA axis hyperactivation by modulating corticotrophin-releasing factor (CRF) receptor interactions, attenuating cortisol release during physical and psychological stress. Facilitates acetylcholine, dopamine, and norepinephrine release, and enhances glucose metabolism in the brain.
100-300mg daily
With meals (fat-containing preferred for absorption). Can be taken morning or evening. Cortisol-blunting effects are relevant for evening/pre-bed dosing in stressed individuals.
Ongoing; no cycling required. Clinical benefits observed from 6-12 weeks.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →